Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docaravimab/Miromavimab - Zydus Cadila

Drug Profile

Docaravimab/Miromavimab - Zydus Cadila

Alternative Names: Anti-rabies monoclonal antibody (Rabimabs) - Zydus Cadila; Anti-rabies monoclonal antibody - Zydus Cadila; Anti-rabies monoclonal antibody cocktail - Zydus Cadila; M777-16-3/MAb 62-71-3; MAB 5; Miromavimab/Docaravimab; Rabies mAb - Zydus Cadila/WHO; Rabimabs; Twinrab

Latest Information Update: 29 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus Cadila
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rabies
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Rabies

Most Recent Events

  • 17 Jun 2020 Cadila Healthcare completes a phase III trial in Rabies in India (IM) (CTRI2017-07-009038)
  • 03 Sep 2019 Preregistration for Rabies in India (IM) before September 2019
  • 03 Sep 2019 Registered for Rabies in India (IM) - first global approval
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top